Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · IEX Real-Time Price · USD
1.960
-0.040 (-2.00%)
At close: Jul 2, 2024, 4:00 PM
1.900
-0.060 (-3.06%)
After-hours: Jul 2, 2024, 6:43 PM EDT
Cardiol Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CRDL stock have an average target of 7.50, with a low estimate of 3.00 and a high estimate of 10. The average target predicts an increase of 282.65% from the current stock price of 1.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRDL stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +410.20% | Jun 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +359.18% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +359.18% | Jun 7, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $6 → $8 | Strong Buy | Maintains | $6 → $8 | +308.16% | May 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +359.18% | May 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.43
from -0.44
EPS Next Year
-0.38
from -0.43
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 15.4M | 68.6M | 190.3M |
| Avg | n/a | n/a | 7.5M | 61.2M | 160.2M |
| Low | n/a | n/a | n/a | 55.6M | 125.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 815.2% | 210.7% |
| Avg | - | - | - | 716.9% | 161.6% |
| Low | - | - | - | 641.7% | 104.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.37 | -0.27 | -0.32 | 0.25 | 1.21 |
| Avg | -0.43 | -0.38 | -0.34 | 0.24 | 1.17 |
| Low | -0.49 | -0.45 | -0.36 | 0.24 | 1.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 393.2% |
| Avg | - | - | - | - | 379.1% |
| Low | - | - | - | - | 360.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.